Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial - Tutt, A; Robson, M; Garber, J E (Lancet, 2010)
et al.